Fig. 2From: The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018PFS landmark analysis of the most important studies in NSCLC 1L. Progression-free survival landmark analysis of the most important studies in non-small-cell lung cancer 1LBack to article page